Stryker stock: CEO keeps surgical robot production in U.S.
Published on 11/19/2026 at 16:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRobotics strategy and investor focus
- CEO Kevin Lobo linked U.S. robot production to intellectual-property protection and said Chinese competitors are not yet an imminent threat.
- Stryker is expanding into soft-tissue surgery through its CMR Surgical investment, exclusive U.S. sales rights and acquisition option.
- Execution, regulatory clearance and hospital adoption remain key factors for the robotics strategy.
Stryker Chair and CEO Kevin Lobo said on Monday, November 16, that the company has no plans to manufacture orthopedic surgical robots in China because intellectual-property protection is a major concern. Fortune reported the comments after Lobo spoke at the Fortune 500 Innovation Forum in Detroit.
U.S. production protects Mako technology
Lobo said Stryker builds its orthopedic robots in the United States and ships them worldwide. He also said Chinese companies are copying other robotic systems, while describing Stryker's approach to Chinese robotics as opportunistic rather than an immediate threat to the business.
The Mako platform has been used in 2.5 million procedures across 47 countries, according to Fortune. Lobo said robots now assist with two of every three Stryker knee replacements, making software, procedure data and intellectual property central to the platform's commercial position.
Soft-tissue robotics adds execution risk
Stryker's robotics strategy also reaches beyond orthopedics. The company agreed in October to invest roughly 400 million US dollars in preferred equity in London-based CMR Surgical, receive exclusive U.S. sales rights for the Versius soft-tissue robot and hold an exclusive option to acquire the company, subject to regulatory approvals.
The move gives Stryker access to a smaller platform aimed at procedures such as gallbladder removal and hernia repair. For investors, the opportunity depends on regulatory progress, hospital adoption and the company's ability to integrate another robotics platform while managing softer hip and knee demand.
Share price and market context
Stryker stock traded at 285.40 euros on Lang & Schwarz at 16:39 CET on Thursday, November 19, 2026, 1.43 percent below the Xetra close of Wednesday, November 18, 2026, at 289.55 euros. The move is separate from the company's robotics strategy and leaves the market focused on execution as well as long-term technology positioning.
Stryker Corporation at a glance
- Company: Stryker Corporation
- ISIN: US8636671013
- Ticker: SYK
- Primary exchange: New York Stock Exchange
- Lang & Schwarz quote: 285.40 euros on November 19, 2026 at 16:39 CET
- Xetra close: 289.55 euros on November 18, 2026
US equities remain the broader market backdrop for the medical-technology group; investors can follow Current market reports.
